دورية أكاديمية
Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody.
| العنوان: | Mast Cell and Eosinophil Activation Are Associated With COVID-19 and TLR-Mediated Viral Inflammation: Implications for an Anti-Siglec-8 Antibody. |
|---|---|
| المؤلفون: | Gebremeskel S; Allakos Inc., Redwood City, CA, United States., Schanin J; Allakos Inc., Redwood City, CA, United States., Coyle KM; Department of Molecular Biology and Biochemistry, Research Centre, Simon Fraser University, Vancouver, BC, Canada., Butuci M; Allakos Inc., Redwood City, CA, United States., Luu T; Allakos Inc., Redwood City, CA, United States., Brock EC; Allakos Inc., Redwood City, CA, United States., Xu A; Allakos Inc., Redwood City, CA, United States., Wong A; Allakos Inc., Redwood City, CA, United States., Leung J; Allakos Inc., Redwood City, CA, United States., Korver W; Allakos Inc., Redwood City, CA, United States., Morin RD; Department of Molecular Biology and Biochemistry, Research Centre, Simon Fraser University, Vancouver, BC, Canada., Schleimer RP; Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Bochner BS; Division of Allergy and Immunology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Youngblood BA; Allakos Inc., Redwood City, CA, United States. |
| المصدر: | Frontiers in immunology [Front Immunol] 2021 Mar 10; Vol. 12, pp. 650331. Date of Electronic Publication: 2021 Mar 10 (Print Publication: 2021). |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: [Lausanne : Frontiers Research Foundation] |
| مواضيع طبية MeSH: | Antigens, CD/*immunology , Antigens, Differentiation, B-Lymphocyte/*immunology , COVID-19/*immunology , Eosinophils/*immunology , Lectins/*immunology , Mast Cells/*immunology , Respiratory Syncytial Virus Infections/*immunology , Respiratory Syncytial Viruses/*immunology , SARS-CoV-2/*immunology , Toll-Like Receptors/*immunology, Animals ; Antibodies, Monoclonal/pharmacology ; Antigens, CD/genetics ; Antigens, CD/metabolism ; Antigens, Differentiation, B-Lymphocyte/genetics ; Antigens, Differentiation, B-Lymphocyte/metabolism ; COVID-19/metabolism ; COVID-19/prevention & control ; COVID-19/virology ; Case-Control Studies ; Cytokines/metabolism ; Disease Models, Animal ; Eosinophils/drug effects ; Eosinophils/metabolism ; Eosinophils/virology ; Host-Pathogen Interactions ; Humans ; Lectins/antagonists & inhibitors ; Lectins/genetics ; Lectins/metabolism ; Mast Cells/drug effects ; Mast Cells/metabolism ; Mast Cells/virology ; Mice, Transgenic ; Peptide Hydrolases/metabolism ; Respiratory Syncytial Virus Infections/metabolism ; Respiratory Syncytial Virus Infections/prevention & control ; Respiratory Syncytial Virus Infections/virology ; Toll-Like Receptors/metabolism |
| مستخلص: | Coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection represents a global health crisis. Immune cell activation via pattern recognition receptors has been implicated as a driver of the hyperinflammatory response seen in COVID-19. However, our understanding of the specific immune responses to SARS-CoV-2 remains limited. Mast cells (MCs) and eosinophils are innate immune cells that play pathogenic roles in many inflammatory responses. Here we report MC-derived proteases and eosinophil-associated mediators are elevated in COVID-19 patient sera and lung tissues. Stimulation of viral-sensing toll-like receptors in vitro and administration of synthetic viral RNA in vivo induced features of hyperinflammation, including cytokine elevation, immune cell airway infiltration, and MC-protease production-effects suppressed by an anti-Siglec-8 monoclonal antibody which selectively inhibits MCs and depletes eosinophils. Similarly, anti-Siglec-8 treatment reduced disease severity and airway inflammation in a respiratory viral infection model. These results suggest that MC and eosinophil activation are associated with COVID-19 inflammation and anti-Siglec-8 antibodies are a potential therapeutic approach for attenuating excessive inflammation during viral infections. Competing Interests: JS, SG, MB, TL, EB, AX, AW, JL,WK, and BY are employees of Allakos and/or own stock options in Allakos. BB and RS did not perform any of the experiments but are paid consultants on the scientific advisory board of Allakos, Inc., and own stock in Allakos. BB and RS are coinventors on existing Siglec-8–related patents and thus may be entitled to a share of royalties received by Johns Hopkins University from Allakos, Inc. on the potential sales of such products. BB and RS are also cofounders of Allakos, which makes him subject to certain restrictions under university policy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Gebremeskel, Schanin, Coyle, Butuci, Luu, Brock, Xu, Wong, Leung, Korver, Morin, Schleimer, Bochner and Youngblood.) |
| References: | Int Arch Allergy Immunol. 2019;180(2):91-102. (PMID: 31401630) Immunol Res. 2020 Jun;68(3):161-168. (PMID: 32524333) Front Immunol. 2020 Sep 18;11:574862. (PMID: 33042157) Immunity. 2020 Jun 16;52(6):910-941. (PMID: 32505227) Nature. 2020 May;581(7807):221-224. (PMID: 32225175) Front Immunol. 2015 May 18;6:238. (PMID: 26042121) Cell. 2019 Oct 3;179(2):417-431.e19. (PMID: 31585081) Mucosal Immunol. 2021 Mar;14(2):366-376. (PMID: 32814824) Int J Mol Sci. 2019 Aug 30;20(17):. (PMID: 31480219) Nat Rev Immunol. 2020 Jun;20(6):363-374. (PMID: 32346093) J Biol Regul Homeost Agents. 2020 Oct 5;34(5):1633-1636. (PMID: 33023287) J Clin Invest. 2020 May 1;130(5):2620-2629. (PMID: 32217835) J Biol Regul Homeost Agents. 2020 Sep 18;34(5):1629-1632. (PMID: 32945158) Curr Probl Cardiol. 2020 Aug;45(8):100618. (PMID: 32439197) J Immunol. 2003 Oct 15;171(8):3977-82. (PMID: 14530316) Traffic. 2005 Nov;6(11):1047-57. (PMID: 16190985) Med Hypotheses. 2020 Oct;143:109856. (PMID: 32460208) Int Arch Allergy Immunol. 1998 Sep;117 Suppl 1:55-8. (PMID: 9758899) Haematologica. 2020 Jan;105(1):5-6. (PMID: 31894094) Circ Res. 2018 Jan 19;122(2):319-336. (PMID: 29348253) JAMA. 2020 Sep 3;:. (PMID: 32880615) J Allergy Clin Immunol. 2015 Nov;136(5):1346-54.e1. (PMID: 25819983) JCI Insight. 2019 Oct 3;4(19):. (PMID: 31465299) J Allergy Clin Immunol. 2020 Oct;146(4):799-807.e9. (PMID: 32710975) Lancet. 2010 Sep 4;376(9743):826-34. (PMID: 20816549) J Immunol. 2009 Dec 15;183(12):7703-9. (PMID: 19933851) J Thromb Thrombolysis. 2020 Oct;50(3):567-579. (PMID: 32627126) Nat Rev Immunol. 2020 Jun;20(6):343-344. (PMID: 32327719) J Allergy Clin Immunol. 2020 Jul;146(1):1-7. (PMID: 32344056) J Invest Dermatol. 2013 Sep;133(9):2170-9. (PMID: 23528820) Elife. 2013 Apr 30;2:e00481. (PMID: 23638300) Nat Rev Immunol. 2014 Jul;14(7):478-94. (PMID: 24903914) Annu Rev Immunol. 2020 Apr 26;38:49-77. (PMID: 32340580) Science. 2020 Aug 7;369(6504):706-712. (PMID: 32527925) FASEB J. 2012 May;26(5):2084-93. (PMID: 22294786) J Clin Invest. 2020 May 1;130(5):2202-2205. (PMID: 32217834) Front Pharmacol. 2020 Aug 06;11:1214. (PMID: 32848802) Nat Rev Immunol. 2020 Jun;20(6):355-362. (PMID: 32376901) Glycobiology. 2016 Jun;26(6):546-52. (PMID: 26911285) Nat Commun. 2020 Dec 9;11(1):6319. (PMID: 33298930) QJM. 2020 Jul 1;113(7):511-512. (PMID: 32315429) J Allergy Clin Immunol. 2012 Sep;130(3):572-84. (PMID: 22935586) J Allergy Clin Immunol. 2020 Jul;146(1):128-136.e4. (PMID: 32425269) PLoS Negl Trop Dis. 2012;6(2):e1505. (PMID: 22363824) Neuroscientist. 2020 Oct-Dec;26(5-6):402-414. (PMID: 32684080) Lancet. 2020 Feb 15;395(10223):497-506. (PMID: 31986264) Nat Med. 2012 May 04;18(5):693-704. (PMID: 22561833) J Allergy Clin Immunol. 2008 Feb;121(2):499-505.e1. (PMID: 18036650) Immunol Rev. 2018 Mar;282(1):121-150. (PMID: 29431212) Nat Commun. 2019 Feb 11;10(1):706. (PMID: 30742008) Cell Host Microbe. 2020 Jun 10;27(6):883-890.e2. (PMID: 32407669) Nature. 2020 Aug;584(7821):463-469. (PMID: 32717743) Biofactors. 2020 May;46(3):306-308. (PMID: 32339387) J Leukoc Biol. 2020 Jul;108(1):73-81. (PMID: 31965606) Cell. 2020 May 28;181(5):1036-1045.e9. (PMID: 32416070) Allergy. 2020 Jul;75(7):1730-1741. (PMID: 32077115) Front Immunol. 2016 Jan 06;6:620. (PMID: 26779180) J Immunol. 2013 May 1;190(9):4458-63. (PMID: 23606723) Lancet. 2020 Feb 15;395(10223):507-513. (PMID: 32007143) Life Sci. 2020 Sep 15;257:118054. (PMID: 32663575) Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651) Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3. (PMID: 32320677) Am J Respir Crit Care Med. 2020 Jun 1;201(11):1372-1379. (PMID: 32242738) Cells. 2020 Dec 24;10(1):. (PMID: 33374255) Mucosal Immunol. 2013 May;6(3):474-84. (PMID: 22990623) Elife. 2015 Mar 18;4:. (PMID: 25783751) Blood. 2007 Sep 1;110(5):1578-86. (PMID: 17495130) |
| معلومات مُعتمدة: | P01 AI145818 United States AI NIAID NIH HHS |
| فهرسة مساهمة: | Keywords: COVID-19; SARS-CoV-2; Siglec-8; Toll-like receptor; eosinophil; lirentelimab; mast cell; viral inflammation |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Antigens, CD) 0 (Antigens, Differentiation, B-Lymphocyte) 0 (Cytokines) 0 (Lectins) 0 (SIGLEC8 protein, human) 0 (Toll-Like Receptors) EC 3.4.- (Peptide Hydrolases) |
| تواريخ الأحداث: | Date Created: 20210329 Date Completed: 20210409 Latest Revision: 20210514 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC7988091 |
| DOI: | 10.3389/fimmu.2021.650331 |
| PMID: | 33777047 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1664-3224 |
|---|---|
| DOI: | 10.3389/fimmu.2021.650331 |